Skip to Content

Jetrea Approval History

  • FDA approved: Yes (First approved October 17th, 2012)
  • Brand name: Jetrea
  • Generic name: ocriplasmin
  • Dosage form: Intravitreal Injection
  • Company: ThromboGenics NV
  • Treatment for: Vitreomacular Adhesion

Jetrea (ocriplasmin) is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.

Development History and FDA Approval Process for Jetrea

Oct 18, 2012Approval FDA Approves Jetrea for Symptomatic Vitreomacular Adhesion in the Eyes
Jul 27, 2012FDA Advisory Committee Recommends ThromboGenics' Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)
Jul  3, 2012ThromboGenics Announces FDA Accepts Filing and Grants Priority Review to Its Biologics License Application for Ocriplasmin Intravitreal Injection
Jun  7, 2012ThromboGenics Receives Notice From FDA of Advisory Committee Meeting for Ocriplasmin
Dec 27, 2011ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.